CN119818670A - 治疗癌症的药物组合 - Google Patents

治疗癌症的药物组合 Download PDF

Info

Publication number
CN119818670A
CN119818670A CN202411827485.1A CN202411827485A CN119818670A CN 119818670 A CN119818670 A CN 119818670A CN 202411827485 A CN202411827485 A CN 202411827485A CN 119818670 A CN119818670 A CN 119818670A
Authority
CN
China
Prior art keywords
sfrp2
antagonist
cells
mab
hsfrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411827485.1A
Other languages
English (en)
Chinese (zh)
Inventor
N·德摩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development filed Critical MUSC Foundation for Research and Development
Publication of CN119818670A publication Critical patent/CN119818670A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202411827485.1A 2018-09-27 2019-09-27 治疗癌症的药物组合 Pending CN119818670A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862737155P 2018-09-27 2018-09-27
US62/737,155 2018-09-27
PCT/US2019/053651 WO2020069439A1 (en) 2018-09-27 2019-09-27 Pharmaceutical combination for the treatment of cancer
CN201980076608.3A CN113454114B (zh) 2018-09-27 2019-09-27 治疗癌症的药物组合

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980076608.3A Division CN113454114B (zh) 2018-09-27 2019-09-27 治疗癌症的药物组合

Publications (1)

Publication Number Publication Date
CN119818670A true CN119818670A (zh) 2025-04-15

Family

ID=69953118

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411827485.1A Pending CN119818670A (zh) 2018-09-27 2019-09-27 治疗癌症的药物组合
CN201980076608.3A Active CN113454114B (zh) 2018-09-27 2019-09-27 治疗癌症的药物组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980076608.3A Active CN113454114B (zh) 2018-09-27 2019-09-27 治疗癌症的药物组合

Country Status (12)

Country Link
US (1) US20210395351A1 (cg-RX-API-DMAC10.html)
EP (1) EP3856784A4 (cg-RX-API-DMAC10.html)
JP (1) JP7451506B2 (cg-RX-API-DMAC10.html)
KR (1) KR102947706B1 (cg-RX-API-DMAC10.html)
CN (2) CN119818670A (cg-RX-API-DMAC10.html)
AU (1) AU2019351267B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021005525A2 (cg-RX-API-DMAC10.html)
CA (1) CA3114173A1 (cg-RX-API-DMAC10.html)
IL (1) IL281782A (cg-RX-API-DMAC10.html)
MX (1) MX2021003274A (cg-RX-API-DMAC10.html)
SG (1) SG11202102865WA (cg-RX-API-DMAC10.html)
WO (1) WO2020069439A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013222A (es) * 2019-05-03 2022-01-06 Genentech Inc Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
WO2025199292A1 (en) * 2024-03-21 2025-09-25 Musc Foundation For Research Development A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285989B1 (en) 2008-05-15 2016-11-16 The University of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
WO2011119524A1 (en) 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
WO2014022774A1 (en) 2012-08-02 2014-02-06 Fred Hutchinson Cancer Research Center Treatment induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
HK1254404A1 (zh) * 2015-06-25 2019-07-19 Advanced Accelerator Applications 治疗过度表达生长抑素受体的神经内分泌肿瘤的方法
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
PL3964529T3 (pl) * 2016-01-22 2025-10-27 MabQuest SA Nieblokujące przeciwciała specyficzne względem pd1
CN110267682A (zh) * 2017-02-14 2019-09-20 诺华股份有限公司 Wnt抑制剂和抗PD-1抗体分子组合的给药方案

Also Published As

Publication number Publication date
BR112021005525A2 (pt) 2021-06-29
CN113454114A (zh) 2021-09-28
WO2020069439A1 (en) 2020-04-02
IL281782A (en) 2021-05-31
US20210395351A1 (en) 2021-12-23
JP2022502434A (ja) 2022-01-11
MX2021003274A (es) 2021-09-28
SG11202102865WA (en) 2021-04-29
CA3114173A1 (en) 2020-04-02
EP3856784A1 (en) 2021-08-04
EP3856784A4 (en) 2022-10-19
CN113454114B (zh) 2024-12-27
AU2019351267A1 (en) 2021-05-13
JP7451506B2 (ja) 2024-03-18
KR102947706B1 (ko) 2026-04-03
AU2019351267B2 (en) 2026-07-23
KR20210065146A (ko) 2021-06-03

Similar Documents

Publication Publication Date Title
KR101831123B1 (ko) 세포내 항원에 대해 지향된 단일 도메인 항체
AU2018351006B2 (en) Anti-CD47 agent-based ovarian cancer therapy
JP7681401B2 (ja) がん処置のためのaxl特異的抗体
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための3剤併用療法
US10335494B2 (en) Combination of aurora kinase inhibitors and anti-CD30 antibodies
KR20150130318A (ko) 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 치료법
KR20210034613A (ko) 퀴놀린 유도체 및 항체의 약물 조합
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
US20240174749A1 (en) Methods of treating cancer with antibodies against tim3
WO2017139468A1 (en) Combination of ifn-gamma with erbb inhibitor for the treatment of cancers
CN113454114B (zh) 治疗癌症的药物组合
TWI765862B (zh) 基於過敏反應素-1拮抗劑之癌免疫增強劑
EP3897613A1 (en) Use of il-1beta binding antibodies
RU2838216C2 (ru) Фармакологическая комбинация для лечения рака
CN121311246A (zh) 癌症治疗与预防的组合疗法
HK40122434A (en) Pharmaceutical combination for the treatment of cancer
KR102544135B1 (ko) c-Kit을 표적으로 하는 면역접합체
KR20250131777A (ko) 암의 치료 및 예방을 위한 조합물
HK40092156B (en) Anti-cd47 agent-based ovarian cancer therapy
HK40036030B (en) Anti-cd47 agent-based ovarian cancer therapy
WO2021038097A1 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
Mom Exploring targeted therapies in oncology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40122434

Country of ref document: HK